SCM
NBIX icon

Sio Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Sio Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,725
Closed -$12.7M – 63
2025
Q2 		$12.7M Sell
100,725
-86,848
-46% -$9.96M 4.84% 7
2025
Q1 		$20.7M Buy
+187,573
New +$23.8M 6.18% 5
2019
Q1 		– Sell
-69,000
Closed -$4.93M – 81
2018
Q4 		$4.93M Buy
+69,000
New +$6.61M 1.79% 21

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sio Capital Management's NBIX Position: Q3 2025 in Review

Sio Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 100,725 shares — an estimated $12.7M sold.

Sio Capital Management first reported a position in NBIX in Q4 2018 and held it in 3 quarters. The position peaked at $20.7M in Q1 2025. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Sio Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Sio Capital Management sold 100,725 Neurocrine Biosciences shares in Q3 2025, an estimated $12.7M.
  • Sio Capital Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 3 quarters.
  • Sio Capital Management's Neurocrine Biosciences position peaked at $20.7M in Q1 2025.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Sio Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.